Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study

Vaccine

Volumn 32, Issue 9, 2014, Pages 1072-1078

  Iaria, Maria Luisa ^a   Fiorentini, Simona ^a   Focà, Emanuele ^a   Zicari, Sonia ^a   Giagulli, Cinzia ^a   Caccuri, Francesca ^a   Francisci, Daniela ^b   Di Perri, Giovanni ^c   Castelli, Francesco ^a   Baldelli, Franco ^b   Caruso, Arnaldo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

HIV 1 matrix protein p17; Peptide based immunotherapy; Therapeutic vaccine

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; AT 20; AT20; DRUG ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; NEUTRALIZING ANTIBODY; PROTEIN P17; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BACKACHE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COUGHING; DRUG DEVELOPMENT; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ERYTHEMA; FOLLOW UP; GASTROENTERITIS; HELICOBACTER INFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; LOW DRUG DOSE; LYMPHADENOPATHY; MULTICENTER STUDY; MYCOSIS; OROPHARYNX PAIN; PATIENT MONITORING; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEROCONVERSION; TREATMENT RESPONSE; VERTIGO; VIREMIA; VIRUS LOAD;

HIV-1 MATRIX PROTEIN P17; PEPTIDE-BASED-IMMUNOTHERAPY; THERAPEUTIC VACCINE;

ADULT; AIDS VACCINES; ANTI-RETROVIRAL AGENTS; ANTIBODIES, NEUTRALIZING; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, HUMORAL; MIDDLE AGED; VACCINES, SYNTHETIC;

EID: 84895059984     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.12.051     Document Type: Article

References (30)

1. + T cell homeostasis and function in advanced HIV disease. Science 1997, 277(5322):11211-11216.
2. Plana M., Garcia F., Gallart T., Tortajada C., Soriano A., Palou E., et al. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 2000, 14(13):1921-1933.
3. Guihot A., Tubiana R., Breton G., Marcelin A., Samri A., Assoumou L., et al. Immune and virological benefit of 10 years of permanent viral control with antiretroviral therapy. AIDS 2010, 24(4):614-617.
4. Nicastri E., Chiesi A., Angeletti C., Sarmati L., Palmisano L., Geraci A., et al. Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART. Journal of Medical Virology 2005, 76(2):153-160.
5. Moore D.M., Hogg R.S., Yip B., Wood E., Tyndall M., Braitstein P., et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. Journal of Acquired Immune Deficiency Syndrome 2005, 40(3):288-293.
6. Imaz A., Falcó V., Ribera E. Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice. AIDS Review 2011, 13(3):180-193.
7. Fiorentini S., Giagulli C., Caccuri F., Magiera A.K., Caruso A. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS. Pharmacology and Therapeutics 2010, 128(3):433-444.
8. De Francesco M.A., Baronio M., Fiorentini S., Signorini C., Bonfanti C., Poiesi C., et al. HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(15):9972-9977.
9. Vitale M., Caruso A., De Francesco M.A., Rodella L., Bozzo L., Garrafa E., et al. HIV-1 matrix protein p17 enhances the proliferative activity of natural killer cells and increases their ability to secrete proinflammatory cytokines. British Journal of Haematology 2003, 120(2):337-343.
10. Marini E., Tiberio L., Caracciolo S., Tosti G., Guzman C.A., Schiaffonati L., et al. HIV-1 matrix protein p17 binds to monocytes and selectively stimulates MCP-1 secretion: role of transcriptional factor AP-1. Cellular Microbiology 2008, 10(3):655-666.
11. Fiorentini S., Riboldi E., Facchetti F., Avolio M., Fabbri M., Tosti G., et al. HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature phenotype. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(10):3867-3872.
12. Naylor P.H., Naylor C.W., Badamchian M., Wada S., Goldstein A.L., Wang S.S., et al. Human immunodeficiency virus contains an epitope immunoreactive with thimosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30. Proceedings of the National Academy of Sciences of the United States of America 1987, 84(9):2951-2955.
13. Buratti E., Tisminetzky S.G., D'Agaro P., Baralle F.E. A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence EEE. Journal of Virology 1997, 71(3):2457-2462.
14. Chargelegue D., Stanley C.M., O'Toole C.M., Colvin B.T., Steward M.W. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression. Clinical and Experimental Immunology 1995, 99(2):175-181.
15. Binley J.M., Klasse P.J., Cao Y., Jones I., Markovitz M., Ho D.D., et al. Differential regulation of the antibody response to Gag and Env proteins of human immunodeficiency virus type 1. Journal of Virology 1997, 71(4):2799-2809.
16. Fiorentini S., Marini E., Caracciolo S., Caruso A. Functions of the HIV-1 matrix protein p17. New Microbiologica 2006, 29(1):1-10.
17. Popovic M., Tenner-Racz K., Pelser C., Stellbrink H.J., van Lunzen J., Lewis G., et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(41):14807-14812.
18. Giagulli C., Magiera A.K., Bugatti A., Caccuri F., Marsico S., Rusnati M., et al. HIV-1 matrix protein p17 binds to the IL-8 receptor CXCR1 and shows IL-8-like chemokine activity on monocytes through Rho/ROCK activation. Blood 2012, 119(10):2274-2283.
19. Caccuri F., Giagulli C., Bugatti A., Benetti A., Alessandri G., Ribatti D., et al. HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(36):14580-14585.
20. Bugatti A., Giagulli C., Urbinati C., Caccuri F., Chiodelli P., Oreste P., et al. Molecular interaction studies of HIV-1 matrix protein p17 and heparin: identification of the heparin-binding motif of p17 as a target for the development of multitarget antagonists. Journal of Biological Chemistry 2013, 288(2):1150-1161.
21. Fiorentini S., Marini E., Bozzo L., Trainini L., Saadoune L., Avolio M., et al. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH. Biopolymers 2004, 76(4):334-343.
22. Fiorentini S., Marsico S., Becker P.D., Iaria M.L., Bruno R., Guzman C.A., et al. Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17. Vaccine 2008, 26(36):4758-4765.
23. Caruso A., Bonfanti C., Colombrita D., De Francesco M.A., De Rango C., Foresti I., et al. Natural antibodies to IFN-γ in man and their increase during viral infection. Journal of Immunology 1990, 144(2):685-690.
24. Jiang J.D., Chu F.N., Naylor P.H., Kirkley J.E., Mandeli J., Wallace J.I., et al. Specific antibody responses to synthetic peptides of HIV-1 p17 correlate with different stages of HIV infection. Journal of Acquired Immune Deficiency Syndrome 1992, 5(4):382-390.
25. García F., Bernaldo de Quirós J.C., Gómez C.E., Perdiguero B., Nájera J.L., Jiménez V., et al. Safand immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: a phase I clinical trial (RISVAC02). Vaccine 2011, 29(46):8309-8316.
26. Fogli M., Torti C., Malacarne F., Fiorentini S., Albani M., Izzo I., et al. Emergence of exhausted B cells in asymptomatic HIV-1-infected patients naïve for HAART is related to reduced immune surveillance. Clinical and Developmental Immunology 2012, 2012:829584. 10.1155/2012/829584.
27. Renga B., Francisci D., D'Amore C., Schiaroli E., Mencarelli A., Cipriani S., et al. The HIV matrix protein p17 subverts nuclear receptors expression and induces a STAT-1-dependent proinflammatory phenotype in monocytes. PLoS ONE 2012, 7(4):e35924.
28. Reither W.E., Blalock J.E., Brunck T.K. Sequence homology between acquired immunodeficiency syndrome virus envelope protein and interleukin-2. Proceedings of the National Academy of Sciences of the United States of America 1986, 83(23):9188-9192.
29. Hoffmann B., Langhoff E., Lindhardt B.O., Odum N., Hyldig-Nielsen J.J., Ryder L.P., et al. Investigation of immunosuppressive properties of inactivated human immunodeficiency virus and possible neutralization of this effect by some patient sera. Cell Immunology 1989, 121(2):336-348.
30. Tsiakalos A., Routsias J.G., Kordossis T., Moutsopoulos H.M., Tzioufas A.G., Sipsas N.V. Fine epitope specificity of anti-erythropoietin antibodies reveals molecular mimicry with HIV-1 p17 protein: a pathogenetic mechanism for HIV-1-related anemia. Journal of Infectious Diseases 2011, 204(6):902-911.